000304294 001__ 304294
000304294 005__ 20250904114814.0
000304294 0247_ $$2doi$$a10.21037/hbsn-2025-316
000304294 0247_ $$2pmid$$apmid:40893741
000304294 0247_ $$2pmc$$apmc:PMC12393116
000304294 0247_ $$2ISSN$$a2304-3881
000304294 0247_ $$2ISSN$$a2304-389X
000304294 037__ $$aDKFZ-2025-01830
000304294 041__ $$aEnglish
000304294 082__ $$a610
000304294 1001_ $$0P:(DE-He78)0c6ebc2a9679701245512d27e35c5ac5$$aOlkus, Alexander$$b0$$eFirst author$$udkfz
000304294 245__ $$aBeyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.
000304294 260__ $$aHong Kong$$bAME Publishing Co.$$c2025
000304294 3367_ $$2DRIVER$$aarticle
000304294 3367_ $$2DataCite$$aOutput Types/Journal article
000304294 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756967976_27123$$xEditorial
000304294 3367_ $$2BibTeX$$aARTICLE
000304294 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304294 3367_ $$00$$2EndNote$$aJournal Article
000304294 500__ $$a#EA:D500#LA:D500#
000304294 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000304294 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304294 650_7 $$2Other$$aImmunotherapy
000304294 650_7 $$2Other$$abiliary tract cancer (BTC)
000304294 650_7 $$2Other$$along-term survival
000304294 7001_ $$0P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDill, Michael$$b1$$eLast author$$udkfz
000304294 773__ $$0PERI:(DE-600)2812398-0$$a10.21037/hbsn-2025-316$$gVol. 14, no. 4, p. 676 - 679$$n4$$p676 - 679$$tHepatobiliary surgery and nutrition$$v14$$x2304-3881$$y2025
000304294 909CO $$ooai:inrepo02.dkfz.de:304294$$pVDB
000304294 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0c6ebc2a9679701245512d27e35c5ac5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304294 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304294 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000304294 9141_ $$y2025
000304294 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEPATOBIL SURG NUTR : 2022$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000304294 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bHEPATOBIL SURG NUTR : 2022$$d2024-12-30
000304294 9202_ $$0I:(DE-He78)D500-20160331$$kD500$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x0
000304294 9201_ $$0I:(DE-He78)D500-20160331$$kD500$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x0
000304294 9200_ $$0I:(DE-He78)D500-20160331$$kD500$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x0
000304294 980__ $$ajournal
000304294 980__ $$aVDB
000304294 980__ $$aI:(DE-He78)D500-20160331
000304294 980__ $$aUNRESTRICTED